Response Biomedical continues global market expansion, signs Guangzhou Wondfo Biotech in China

Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that the Company has signed a second partner, Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) in China to sell the Company’s diagnostic products, expanding its strategic presence in this important global market.

“We have already seen great success in China with our first partner, O&D Biotech Co., Ltd. China (O&D), selling our co-branded RAMP® cardiac products over the past few years”

“We have already seen great success in China with our first partner, O&D Biotech Co., Ltd. China (O&D), selling our co-branded RAMP® cardiac products over the past few years,” said S. Wayne Kay, Chief Executive Officer. “In 2009, we recognized a significant portion of our revenues from sales in China. We are pleased to sign the Wondfo agreement and with representation by two strong partners in this region, we expect sales in China to continue to make an important contribution to our overall revenues.”

"China is an exciting and growing market and our continued international market expansion is extremely important to our overall strategy. Wondfo will be selling private label cardiac products, while O&D sells co-branded RAMP® products on both the RAMP® and RAMP® 200 Readers."